Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more
Scisparc Ltd (SPRC) - Net Assets
Latest net assets as of September 2025: $-81.00K USD
Based on the latest financial reports, Scisparc Ltd (SPRC) has net assets worth $-81.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.14 Million) and total liabilities ($5.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-81.00K |
| % of Total Assets | -1.58% |
| Annual Growth Rate | 1.38% |
| 5-Year Change | 525.1% |
| 10-Year Change | 674.24% |
| Growth Volatility | 2382.43 |
Scisparc Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Scisparc Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scisparc Ltd (2006–2024)
The table below shows the annual net assets of Scisparc Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.94 Million | -6.76% |
| 2023-12-31 | $9.59 Million | +48.66% |
| 2022-12-31 | $6.45 Million | -20.78% |
| 2021-12-31 | $8.14 Million | +469.30% |
| 2020-12-31 | $1.43 Million | +10114.29% |
| 2019-12-31 | $14.00K | -81.82% |
| 2018-12-31 | $77.00K | -99.08% |
| 2017-12-31 | $8.39 Million | +1364.78% |
| 2016-12-31 | $572.71K | -50.40% |
| 2015-12-31 | $1.15 Million | +1092.44% |
| 2014-12-31 | $-116.33K | -111.69% |
| 2013-12-31 | $995.26K | +155.57% |
| 2012-12-31 | $389.43K | -86.78% |
| 2011-12-31 | $2.95 Million | -42.17% |
| 2010-12-31 | $5.09 Million | -9.66% |
| 2009-12-31 | $5.64 Million | -24.99% |
| 2008-12-31 | $7.52 Million | -20.12% |
| 2007-12-31 | $9.41 Million | +34.73% |
| 2006-12-31 | $6.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scisparc Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7222808400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $70.89 Million | 869.34% |
| Other Comprehensive Income | $497.00K | 6.10% |
| Other Components | $11.75 Million | 144.05% |
| Total Equity | $8.15 Million | 100.00% |
Scisparc Ltd Competitors by Market Cap
The table below lists competitors of Scisparc Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Raptis Group Ltd
AU:RPG
|
$1.93 Million |
|
GRAPHEX GROUP LTD HD -01
F:5100
|
$1.94 Million |
|
Jiankun International Bhd
KLSE:8923
|
$1.94 Million |
|
Cyanotech Corporation
NASDAQ:CYAN
|
$1.94 Million |
|
Aclarion Inc
NASDAQ:ACON
|
$1.93 Million |
|
Archies Limited
NSE:ARCHIES
|
$1.93 Million |
|
Drago entertainment S.A.
WAR:DGE
|
$1.93 Million |
|
HELIX Resources Ltd
AU:HLX
|
$1.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scisparc Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,614,000 to 8,154,000, a change of 540,000 (7.1%).
- Net loss of 6,284,000 reduced equity.
- New share issuances of 6,255,000 increased equity.
- Other comprehensive income decreased equity by 11,282,000.
- Other factors increased equity by 11,851,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.28 Million | -77.07% |
| Share Issuances | $6.25 Million | +76.71% |
| Other Comprehensive Income | $-11.28 Million | -138.36% |
| Other Changes | $11.85 Million | +145.34% |
| Total Change | $- | 7.09% |
Book Value vs Market Value Analysis
This analysis compares Scisparc Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.35x to 3.34x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $13.56 | $4.68 | x |
| 2007-12-31 | $15.94 | $4.68 | x |
| 2008-12-31 | $9.75 | $4.68 | x |
| 2009-12-31 | $6.09 | $4.68 | x |
| 2010-12-31 | $4.95 | $4.68 | x |
| 2011-12-31 | $1.13 | $4.68 | x |
| 2012-12-31 | $-0.09 | $4.68 | x |
| 2013-12-31 | $0.10 | $4.68 | x |
| 2014-12-31 | $0.00 | $4.68 | x |
| 2015-12-31 | $0.05 | $4.68 | x |
| 2016-12-31 | $0.02 | $4.68 | x |
| 2017-12-31 | $0.07 | $4.68 | x |
| 2018-12-31 | $0.02 | $4.68 | x |
| 2019-12-31 | $0.00 | $4.68 | x |
| 2020-12-31 | $1.00 | $4.68 | x |
| 2021-12-31 | $10.31 | $4.68 | x |
| 2022-12-31 | $7.33 | $4.68 | x |
| 2023-12-31 | $3.73 | $4.68 | x |
| 2024-12-31 | $1.40 | $4.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scisparc Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -481.16%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.27x
- Recent ROE (-77.07%) is above the historical average (-2356.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -24.65% | 0.00% | 0.00x | 1.61x | $-2.42 Million |
| 2007 | -57.73% | 0.00% | 0.00x | 1.80x | $-5.73 Million |
| 2008 | -62.83% | 0.00% | 0.00x | 1.73x | $-4.22 Million |
| 2009 | -69.11% | 0.00% | 0.00x | 3.29x | $-2.94 Million |
| 2010 | -110.08% | -215.06% | 0.17x | 3.09x | $-3.87 Million |
| 2011 | -429.32% | 0.00% | 0.00x | 5.11x | $-3.81 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.35 Million |
| 2013 | 5.61% | 0.00% | 0.00x | 1.60x | $-46.55K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.85 Million |
| 2015 | -193.14% | 0.00% | 0.00x | 1.27x | $-2.66 Million |
| 2016 | -347.53% | 0.00% | 0.00x | 2.17x | $-2.05 Million |
| 2017 | -76.82% | -1282.14% | 0.05x | 1.18x | $-7.06 Million |
| 2018 | -4607.03% | -1017.06% | 0.18x | 24.65x | $-8.54 Million |
| 2019 | -38300.00% | -1076.71% | 0.43x | 82.43x | $-5.36 Million |
| 2020 | -245.24% | -637.64% | 0.21x | 1.79x | $-3.65 Million |
| 2021 | -71.26% | -542.66% | 0.11x | 1.22x | $-6.62 Million |
| 2022 | -40.19% | -192.43% | 0.13x | 1.64x | $-3.24 Million |
| 2023 | -67.27% | -177.91% | 0.26x | 1.47x | $-5.88 Million |
| 2024 | -77.07% | -481.16% | 0.13x | 1.27x | $-7.10 Million |
Industry Comparison
This section compares Scisparc Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scisparc Ltd (SPRC) | $-81.00K | -24.65% | N/A | $1.93 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |